NCT01353716View on ClinicalTrials.gov

Dolutegravir Renal Impairment Study

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Infection, Human Immunodeficiency Virus
Interventions
DRUG

Dolutegravir 50 mg

Dolutegravir is an experimental drug in the integrase inhibitor class of HIV medications. There will be a one single dose of 50 mg.

Trial Locations (1)

55404

GSK Investigational Site, Minneapolis

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (2)

Shionogi
GlaxoSmithKline
All Listed Sponsors
collaborator

Shionogi

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY